| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.33B | 9.92 | 70.86 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 720.1M | 4.25 | 11.18 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 881.27M | 2.22 | -1.73 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 572.64M | 7.30 | -2.38 | -117.82% | 0.18 | |||
| NKTRNektar Therapeutics | 719.28M | 35.36 | -4.07 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IMNMImmunome, Inc. | 2.52B | 22.85 | -4.57 | -35.5% | -23.01% | -84.4% | 0.03 | |
| IBRXImmunityBio, Inc. | 3.89B | 3.95 | -6.37 | 22.71% | -422.28% | |||
| NRIXNurix Therapeutics, Inc. | 1.91B | 18.86 | -6.55 | -29.15% | -292.5% | -65.76% | 0.05 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 44K | 73K | 209K | 685K | 1.81M | 571K | 551K |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -44K | -73K | -209K | -685K | -1.81M | -571K | -551K |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | -0.66% | -1.86% | -2.28% | -1.64% | 0.68% | 0.04% |
| Operating Expenses | 12.74M | 12.36M | 19.24M | 36.8M | 47.31M | 36.49M | 31.11M |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 4.51M | 4.01M | 7.53M | 15.13M | 17.73M | 18.77M | 12.48M |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 8.23M | 8.35M | 11.92M | 21.66M | 29.58M | 18.3M | 18.63M |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 28K | 0 | -209K | 0 | 0 | -571K | 0 |
| Operating Income | -12.74M | -12.44M | -19.45M | -37.48M | -49.12M | -37.06M | -31.66M |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | 0.02% | -0.56% | -0.93% | -0.31% | 0.25% | 0.15% |
| EBITDA | -12.7M | -12.36M | -19.24M | -36.8M | -47.31M | -33.39M | -31.11M |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | - | 0.03% | -0.56% | -0.91% | -0.29% | 0.29% | 0.07% |
| D&A (Non-Cash Add-back) | 44K | 73K | 209K | 685K | 1.81M | 3.68M | 551K |
| EBIT | -12.71M | -14.48M | -18.41M | -36.12M | -48.37M | -36.96M | -30.07M |
| Net Interest Income | 0 | -2.25M | -1.69M | 130K | 1.56M | 3.48M | 2.46M |
| Interest Income | 0 | 2.26K | 1.69K | 800K | 1.78M | 3.62M | 2.55M |
| Interest Expense | 327K | 2.26M | 1.69M | 670K | 219K | 144K | 90K |
| Other Income/Expense | -299K | -4.3M | -649K | 688K | 532K | 2.96M | 1.51M |
| Pretax Income | -13.04M | -16.74M | -20.1M | -36.79M | -48.59M | -34.1M | -30.16M |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -13.04M | -16.74M | -20.1M | -36.79M | -48.59M | -34.1M | -30.16M |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | - | -0.28% | -0.2% | -0.83% | -0.32% | 0.3% | 0.12% |
| Net Income (Continuing) | -13.04M | -16.74M | -20.1M | -36.79M | -48.59M | -34.1M | -30.16M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -19.03 | -0.65 | -0.67 | -1.33 | -1.58 | -1.22 | -1.20 |
| EPS Growth % | - | 0.97% | -0.03% | -0.99% | -0.19% | 0.23% | 0.02% |
| EPS (Basic) | -19.03 | -0.65 | -0.67 | -1.33 | -1.58 | -1.22 | -1.20 |
| Diluted Shares Outstanding | 685.16K | 29.33M | 30.59M | 27.71M | 30.7M | 27.95M | 25.12M |
| Basic Shares Outstanding | 685.16K | 29.33M | 30.59M | 27.71M | 30.7M | 27.95M | 25.12M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 1.28M | 502K | 20.08M | 148.54M | 108.59M | 67.25M | 41.93M |
| Cash & Short-Term Investments | 653K | 251K | 16.6M | 147.62M | 107.12M | 65.76M | 41.34M |
| Cash Only | 653K | 251K | 16.6M | 7.16M | 17.8M | 13.01M | 9.99M |
| Short-Term Investments | 0 | 0 | 0 | 140.46M | 89.32M | 52.75M | 31.34M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 123K | 0 | 2.1M | 374K | 344K | 325K | 120K |
| Total Non-Current Assets | 570K | 715K | 1.35M | 4.68M | 9.79M | 7.12M | 3.43M |
| Property, Plant & Equipment | 123K | 268K | 1.27M | 4.64M | 9.72M | 7.04M | 3.38M |
| Fixed Asset Turnover | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 447K | 447K | 86K | 39K | 63K | 86K | 48K |
| Total Assets | 1.85M | 1.22M | 21.43M | 153.22M | 118.38M | 74.37M | 45.36M |
| Asset Turnover | - | - | - | - | - | - | - |
| Asset Growth % | - | -0.34% | 16.61% | 6.15% | -0.23% | -0.37% | -0.39% |
| Total Current Liabilities | 2.66M | 21.71M | 4.83M | 4.89M | 9.07M | 5.64M | 5.45M |
| Accounts Payable | 1.11M | 3.45M | 3.88M | 2.46M | 4.47M | 1.69M | 1.25M |
| Days Payables Outstanding | 9.19K | 17.25K | 6.78K | 1.31K | 903.01 | 1.08K | 826.72 |
| Short-Term Debt | 696K | 16.05M | 0 | 0 | 0 | 0 | 2.32M |
| Deferred Revenue (Current) | 652K | 1000K | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 207K | -1.96M | 0 | 0 | 0 | 0 | 0 |
| Current Ratio | 0.48x | 0.02x | 4.16x | 30.38x | 11.98x | 11.92x | 7.70x |
| Quick Ratio | 0.48x | 0.02x | 4.16x | 30.38x | 11.98x | 11.92x | 7.70x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 52.67M | 48.16M | 705K | 1.82M | 5.9M | 3.84M | 1.53M |
| Long-Term Debt | 4.05M | 0 | 567K | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 86K | 1.67M | 5.9M | 3.77M | 1.53M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 48.62M | 48.16M | 52K | 149K | 0 | 67K | 0 |
| Total Liabilities | 55.33M | 69.88M | 5.54M | 6.71M | 14.97M | 9.48M | 6.97M |
| Total Debt | 4.75M | 16.05M | 685K | 2.35M | 8.03M | 6.21M | 3.85M |
| Net Debt | 4.09M | 15.8M | -15.91M | -4.8M | -9.76M | -6.8M | -6.15M |
| Debt / Equity | - | - | 0.04x | 0.02x | 0.08x | 0.10x | 0.10x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | -38.96x | -5.51x | -11.52x | -55.94x | -224.29x | -257.39x | -351.81x |
| Total Equity | -53.48M | -68.66M | 15.89M | 146.51M | 103.41M | 64.89M | 38.39M |
| Equity Growth % | - | -0.28% | 1.23% | 8.22% | -0.29% | -0.37% | -0.41% |
| Book Value per Share | -78.05 | -2.34 | 0.52 | 5.29 | 3.37 | 2.32 | 1.53 |
| Total Shareholders' Equity | -53.48M | -68.66M | 15.89M | 146.51M | 103.41M | 64.89M | 38.39M |
| Common Stock | 2K | 2K | 0 | 3K | 3K | 3K | 3K |
| Retained Earnings | -75.57M | -92.31M | -112.41M | -149.21M | -197.79M | -231.9M | -262.05M |
| Treasury Stock | -22.09M | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -314K | -2K | 0 | -333K | -1M | -209K | -13K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -10.31M | -8.57M | -17.7M | -30.26M | -39.03M | -32.02M | -24.67M |
| Operating CF Margin % | - | - | - | - | - | - | - |
| Operating CF Growth % | - | 0.17% | -1.07% | -0.71% | -0.29% | 0.18% | 0.23% |
| Net Income | -13.04M | -16.74M | -20.1M | -36.79M | -48.59M | -34.1M | -30.16M |
| Depreciation & Amortization | 44K | 73K | 209K | 685K | 1.35M | 1.35M | 1.32M |
| Stock-Based Compensation | 1.19M | 0 | 1.49M | 5.66M | 5.81M | 4.45M | 3.13M |
| Deferred Taxes | 0 | 0 | 0 | 19K | 0 | 0 | 0 |
| Other Non-Cash Items | 349K | 4.63M | 1.09M | 57K | 1.4M | 603K | 1.52M |
| Working Capital Changes | 1.49M | 3.47M | -397K | 117K | 1.01M | -4.33M | -489K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 931K | 2.34M | 335K | -1.43M | 2.02M | -2.33M | -445K |
| Cash from Investing | -31K | -53K | -1.4M | -143.12M | 49.95M | 38.41M | 22.44M |
| Capital Expenditures | -31K | -53K | -1.21M | -2.03M | -321K | -180K | -146K |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 750K | 8.22M | 35.45M | 163.94M | -287K | -11.17M | -787K |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 0 | 0 | -2.08M | 109K | 0 | -76K | -10K |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -10.34M | -8.62M | -18.91M | -32.28M | -39.35M | -32.2M | -24.82M |
| FCF Margin % | - | - | - | - | - | - | - |
| FCF Growth % | - | 0.17% | -1.19% | -0.71% | -0.22% | 0.18% | 0.23% |
| FCF per Share | -15.10 | -0.29 | -0.62 | -1.17 | -1.28 | -1.15 | -0.99 |
| FCF Conversion (FCF/Net Income) | 0.79x | 0.51x | 0.88x | 0.82x | 0.80x | 0.94x | 0.82x |
| Interest Paid | 0 | 0 | 12K | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -126.47% | -45.31% | -38.88% | -40.52% | -58.4% |
| Return on Invested Capital (ROIC) | - | - | - | -39.68% | -31.31% | -36.64% | -52.58% |
| Debt / Equity | - | - | 0.04x | 0.02x | 0.08x | 0.10x | 0.10x |
| Interest Coverage | -38.96x | -5.51x | -11.52x | -55.94x | -224.29x | -257.39x | -351.81x |
| FCF Conversion | 0.79x | 0.51x | 0.88x | 0.82x | 0.80x | 0.94x | 0.82x |
Sensei Biotherapeutics, Inc. (SNSE) reported $-4.9M in revenue for fiscal year 2024.
Sensei Biotherapeutics, Inc. (SNSE) grew revenue by 0.0% over the past year. Growth has been modest.
Sensei Biotherapeutics, Inc. (SNSE) reported a net loss of $24.1M for fiscal year 2024.
Sensei Biotherapeutics, Inc. (SNSE) has a return on equity (ROE) of -58.4%. Negative ROE indicates the company is unprofitable.
Sensei Biotherapeutics, Inc. (SNSE) had negative free cash flow of $22.4M in fiscal year 2024, likely due to heavy capital investments.